CA3069016A1 - Bicyclic urea kinase inhibitors and uses thereof - Google Patents

Bicyclic urea kinase inhibitors and uses thereof Download PDF

Info

Publication number
CA3069016A1
CA3069016A1 CA3069016A CA3069016A CA3069016A1 CA 3069016 A1 CA3069016 A1 CA 3069016A1 CA 3069016 A CA3069016 A CA 3069016A CA 3069016 A CA3069016 A CA 3069016A CA 3069016 A1 CA3069016 A1 CA 3069016A1
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
compound
alkyl
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3069016A
Other languages
English (en)
French (fr)
Inventor
Nathanael S. Gray
Yanke LIANG
Hwan Geun Choi
Thomas Sundberg
Alykhan SHAMJI
Ramnik Xavier
David E. Fisher
Nisma MUJAHID
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Dana Farber Cancer Institute Inc
Broad Institute Inc
Original Assignee
General Hospital Corp
Dana Farber Cancer Institute Inc
Broad Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Dana Farber Cancer Institute Inc, Broad Institute Inc filed Critical General Hospital Corp
Publication of CA3069016A1 publication Critical patent/CA3069016A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
CA3069016A 2016-07-05 2017-07-05 Bicyclic urea kinase inhibitors and uses thereof Pending CA3069016A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662358524P 2016-07-05 2016-07-05
US62/358,524 2016-07-05
PCT/US2017/040722 WO2018009544A1 (en) 2016-07-05 2017-07-05 Bicyclic urea kinase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CA3069016A1 true CA3069016A1 (en) 2018-01-11

Family

ID=59351134

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3069016A Pending CA3069016A1 (en) 2016-07-05 2017-07-05 Bicyclic urea kinase inhibitors and uses thereof

Country Status (10)

Country Link
US (3) US10954242B2 (cg-RX-API-DMAC7.html)
EP (2) EP3481830B1 (cg-RX-API-DMAC7.html)
JP (1) JP7277357B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190075043A (cg-RX-API-DMAC7.html)
CN (1) CN110225914A (cg-RX-API-DMAC7.html)
AU (1) AU2017291812B2 (cg-RX-API-DMAC7.html)
CA (1) CA3069016A1 (cg-RX-API-DMAC7.html)
ES (1) ES2920823T3 (cg-RX-API-DMAC7.html)
IL (1) IL264106B (cg-RX-API-DMAC7.html)
WO (1) WO2018009544A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2954186A1 (en) 2014-07-21 2016-01-28 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
WO2018009544A1 (en) 2016-07-05 2018-01-11 The Broad Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
US11241435B2 (en) 2016-09-16 2022-02-08 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
EP3589284A4 (en) * 2017-02-28 2020-12-16 The General Hospital Corporation USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS
SG11202009195WA (en) * 2018-03-30 2020-10-29 Agios Pharmaceuticals Inc Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
WO2020027200A1 (ja) * 2018-08-01 2020-02-06 小野薬品工業株式会社 軟骨関連疾患治療剤
WO2021062327A1 (en) * 2019-09-27 2021-04-01 Jubilant Biosys Limited Fused pyrimidine compounds, compositions and medicinal applications thereof
GB201915828D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915829D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915831D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
CN115916966A (zh) * 2020-01-30 2023-04-04 加利福尼亚大学董事会 Strad结合剂及其用途
AU2021262482A1 (en) * 2020-04-28 2023-01-05 Iomx Therapeutics Ag Bicyclic kinase inhibitors and uses thereof
ES3037417T3 (en) 2020-05-14 2025-10-01 Rhizen Pharmaceuticals Ag Purine derivatives as sik-3 inhibitors
BR112023004179A2 (pt) * 2020-09-16 2023-04-11 Axceso Biopharma Co Ltd Composto de pirimido pirimidinona e composição farmacêutica compreendendo o mesmo
WO2022061312A1 (en) * 2020-09-21 2022-03-24 Soltego, Inc. Sik inhibitors and methods of use thereof
CN116801878A (zh) * 2020-10-05 2023-09-22 达纳-法伯癌症研究所股份有限公司 Her2的有效和选择性抑制剂
CN116744943A (zh) * 2020-12-04 2023-09-12 达因疗法公司 抗体-寡核苷酸复合物及其用途
WO2022165530A1 (en) * 2021-02-01 2022-08-04 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
KR20230053049A (ko) * 2021-10-13 2023-04-21 서울대학교산학협력단 류마티스 관절염 예방 또는 치료용 약학적 조성물 및 건강기능식품
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用
CN117547615B (zh) * 2023-09-26 2024-12-06 首都医科大学宣武医院 一种纳米囊泡及其制备方法和应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4231559B2 (ja) 1997-04-23 2009-03-04 オリザ油化株式会社 リポキシゲナーゼ阻害剤
JP2002516327A (ja) * 1998-05-26 2002-06-04 ワーナー−ランバート・カンパニー 細胞増殖の阻害剤としての二環式ピリミジンおよび二環式３，４−ジヒドロピリミジン
CN1150195C (zh) 1998-10-23 2004-05-19 霍夫曼-拉罗奇有限公司 双环氮杂环
WO2003090688A2 (en) 2002-04-24 2003-11-06 Van Andel Research Institute Enhancement of human epidermal melanogenesis
US7084270B2 (en) 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
WO2004018669A1 (ja) 2002-08-21 2004-03-04 Proteinexpress Co., Ltd. 塩誘導性キナーゼ２及びその用途
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
US7112676B2 (en) * 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
RS20050363A (sr) 2002-11-28 2007-11-15 Schering Aktiengesellschaft, Chk-,Pdk- I Akt-INHIBITORNI PIRIMIDINI, NJIHOVA PROIZVODNJA I UPOTREBA KAO FARMACEUTSKIH SREDSTAVA
CA2521124A1 (en) * 2003-04-10 2004-10-21 F. Hoffmann-La Roche Ag Pyrimido compounds
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
CA2533774A1 (en) * 2003-07-29 2005-02-10 Irm Llc Compounds and compositions as protein kinase inhibitors
CA2567662C (en) 2004-06-10 2012-11-27 Irm Llc Compounds and compositions as protein kinase inhibitors
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
ATE425166T1 (de) * 2004-08-31 2009-03-15 Hoffmann La Roche Amidderivate von 3-phenyldihydropyrimidoä4,5- düpyrimidinonen, deren herstellung und verwendung als pharmazeutische mittel
WO2006024545A1 (en) 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
EP1841760B1 (en) 2004-12-30 2011-08-10 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
EA200702073A1 (ru) 2005-03-25 2008-12-30 Глэксо Груп Лимитед Способ получения пиридо[2,3-d]пиримидин-7-оновых и 3,4-дигидропиримидо[4,5-d]пиримидин-2(1н)-оновых производных
MX2007015610A (es) * 2005-06-10 2008-02-21 Irm Llc Compuestos que mantienen la fluripotencia de las celulas totipotentes embrionarias.
CN101336237B (zh) 2005-12-21 2015-09-30 诺华股份有限公司 作为fgf抑制剂的嘧啶基芳基脲衍生物
EP2018167A4 (en) * 2006-05-15 2010-07-14 Irm Llc COMPOSITIONS AND METHODS AS INHIBITORS OF FGF RECEPTOR KINASES
WO2008060248A1 (en) 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
JP5779778B2 (ja) 2007-11-28 2015-09-16 ダナ−ファーバー キャンサー インスティテュート インク．Ｄａｎａ−Ｆａｒｂｅｒ Ｃａｎｃｅｒ Ｉｎｓｔｉｔｕｔｅ， Ｉｎｃ． Ｂｃｒ−ａｂｌの低分子のミリスチン酸エステル阻害剤及びその使用方法
WO2009122180A1 (en) 2008-04-02 2009-10-08 Medical Research Council Pyrimidine derivatives capable of inhibiting one or more kinases
WO2009152027A1 (en) 2008-06-12 2009-12-17 Merck & Co., Inc. 5,7-dihydro-6h-pyrrolo[2,3-d]pyrimidin-6-one derivatives for mark inhibition
WO2010017047A1 (en) 2008-08-05 2010-02-11 Merck & Co., Inc. Therapeutic compounds
WO2010067888A1 (en) * 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dihydropyrimidopyrimidine derivatives
EP2488526B1 (en) 2009-10-14 2013-07-24 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
CN102816162B (zh) * 2011-06-10 2016-04-27 中国科学院广州生物医药与健康研究院 嘧啶并嘧啶酮类化合物及其药用组合物和应用
US9090630B2 (en) 2011-09-30 2015-07-28 Oncodesign S.A. Macrocyclic FLT3 kinase inhibitors
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
GB201204384D0 (en) 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
LT2841428T (lt) 2012-04-24 2018-12-10 Vertex Pharmaceuticals Incorporated Dnr-pk inhibitoriai
GB201212960D0 (en) * 2012-07-20 2012-09-05 Common Services Agency Erythroid production
JP5683634B2 (ja) * 2012-11-28 2015-03-11 株式会社ショーワ 圧力緩衝装置
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
WO2014138485A1 (en) * 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
EA036160B1 (ru) * 2013-03-15 2020-10-08 Селджен Кар Ллс Гетероарильные соединения и их применение
AU2014230125A1 (en) 2013-03-15 2015-10-29 Oncodesign S.A. Macrocyclic salt-inducible kinase inhibitors
US9783504B2 (en) 2013-07-09 2017-10-10 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
CN104418860B (zh) * 2013-08-20 2016-09-07 中国科学院广州生物医药与健康研究院 嘧啶并杂环类化合物及其药用组合物和应用
CA2954186A1 (en) 2014-07-21 2016-01-28 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
CA2954187C (en) 2014-07-21 2022-08-16 Dana-Farber Cancer Institute, Inc. Macrocyclic kinase inhibitors and uses thereof
EP3536323A1 (en) 2014-08-08 2019-09-11 Dana Farber Cancer Institute, Inc. Uses of salt-inducible kinase (sik) inhibitors
KR101850282B1 (ko) 2014-11-26 2018-05-31 한국과학기술연구원 단백질 키나아제 저해제로 유용한 헤테로아릴아민 유도체
CN104482860B (zh) 2014-12-05 2017-10-31 浙江大学宁波理工学院 鱼类形态参数自动测量装置和方法
WO2018009544A1 (en) 2016-07-05 2018-01-11 The Broad Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
US11241435B2 (en) 2016-09-16 2022-02-08 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
EP3589284A4 (en) * 2017-02-28 2020-12-16 The General Hospital Corporation USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS

Also Published As

Publication number Publication date
IL264106B (en) 2022-04-01
JP7277357B2 (ja) 2023-05-18
AU2017291812B2 (en) 2023-12-14
US10954242B2 (en) 2021-03-23
EP4047001A2 (en) 2022-08-24
US20190315752A1 (en) 2019-10-17
ES2920823T3 (es) 2022-08-10
IL264106A (en) 2019-01-31
JP2019527682A (ja) 2019-10-03
CN110225914A (zh) 2019-09-10
EP4047001A3 (en) 2022-11-30
US11725011B2 (en) 2023-08-15
US20230234959A1 (en) 2023-07-27
EP3481830A1 (en) 2019-05-15
WO2018009544A1 (en) 2018-01-11
US12398145B2 (en) 2025-08-26
EP3481830B1 (en) 2022-02-16
US20210147425A1 (en) 2021-05-20
US20200317675A9 (en) 2020-10-08
AU2017291812A1 (en) 2019-02-21
KR20190075043A (ko) 2019-06-28

Similar Documents

Publication Publication Date Title
US12398145B2 (en) Bicyclic urea kinase inhibitors and uses thereof
US12209076B2 (en) Imidazolyl kinase inhibitors and uses thereof
CA2954187C (en) Macrocyclic kinase inhibitors and uses thereof
CA2955074A1 (en) Diazepane derivatives and uses thereof
CA2955077A1 (en) Dihydropteridinone derivatives and uses thereof
CA2936871A1 (en) Dihydropteridinone derivatives and uses thereof
HK40070345A (en) Bicyclic urea kinase inhibitors and uses thereof
WO2024259178A1 (en) Glycogen synthase kinase 3 inhibitors and uses thereof
HK40008957B (en) Bicyclic urea kinase inhibitors and uses thereof
EP4601637A2 (en) Glycogen synthase kinase 3 inhibitors and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220406

EEER Examination request

Effective date: 20220406

EEER Examination request

Effective date: 20220406

EEER Examination request

Effective date: 20220406

EEER Examination request

Effective date: 20220406

EEER Examination request

Effective date: 20220406

EEER Examination request

Effective date: 20220406